NEW YORK and SHANGHAI, May 26,
2020 /PRNewswire/ -- Cellular Biomedicine Group Inc.
(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm
engaged in the drug development of immunotherapies for cancer and
stem cell therapies for degenerative diseases, has announced
that the 2020 Annual Meeting of Stockholders (the "Annual Meeting")
will be held at 9:00 a.m. Eastern Standard
Time on Friday, June 26, 2020, at Aloft Long Island City –
Manhattan View, 27-45 Jackson Avenue, Long Island City, New York 11101. Stockholders
of record as of April 27, 2020 are
authorized and asked to vote in the manner directed in the proxy
materials.
Upon receiving a Notice of Internet Availability of Proxy
Materials, stockholders may view the proxy statement and related
materials online or request a printed copy at
www.iproxydirect.com/CBMG. Stockholders may vote online, by phone
or by mail, according to the instructions on the proxy, no later
than 11:59pm, Thursday, June 25, 2020, EST. For stocks held in
the name of a bank, broker or other nominee, please check with your
bank, broker or nominee and follow the voting instructions it
provides. Please email sarah.kelly@cellbiomedgroup.com if you
have questions about the Annual Meeting or have not received your
Notice of Internet Availability of Proxy Materials or separate
voting instructions from your bank, broker or other nominee by post
or by email.
The Company is closely monitoring government directives and will
comply with all COVID-19 health and safety rules for our Annual
Meeting. As New York has shown
improvement in meeting the reopen criteria we continue to
plan for the Annual Meeting to take place as scheduled. However,
due to the evolving nature of the pandemic and its impacts, future
developments may still cause disruption to the Annual Meeting
schedule. We will continue to monitor the fluid situation. In the
event it is not possible or advisable to hold the Annual Meeting as
currently planned, we will announce any additional or alternative
arrangements for the meeting, which may include a change in venue.
We will provide updates regarding the Annual Meeting by press
release and filing with the Securities and Exchange Commission as
well as on our website at https://www.cellbiomedgroup.com/.
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China
using products from its integrated GMP laboratory. The Company's
GMP facilities in China,
consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory
of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy
Technology Innovation and Application Center" with Thermo Fisher
Scientific. These partnerships focus on improving manufacturing
processes for cell therapies. CBMG currently has ongoing CAR-T
Phase I clinical trials in China.
The China NMPA (formerly CFDA) approved the Company's IND
application for a Phase II trial for AlloJoin®, CBMG's
"Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee
Osteoarthritis (KOA), and has accepted the Company's IND
application for a Phase II trial for ReJoin® autologous haMPC
therapy for the treatment of KOA. The NMPA has also accepted CBMG's
dossier for an IND application for clinical trials of anti-BCMA
CAR-T. CBMG is included in the broad-market Russell 3000® Index the
small-cap Russell 2000® Index and the Loncar China BioPharma index.
To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, specific
activities, and other statements that are not descriptions of
historical facts, include our plans for holding the 2020 Annual
Meeting of Stockholders, may be forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include any risks detailed from time to time in CBMG's reports
filed with the Securities and Exchange Commission, Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports
on Form 8-K, including risks relating to the impact of the COVID-19
pandemic on our operations, including risks associated with the
evolving COVID-19 pandemic and actions taken in response to it.
Generally, the words "believes," "anticipates," "may," "will,"
"should," "could," "expect," "plans," "intend," "estimate,"
"projects," "presents," "potential," "continue" and similar
expressions or the negative thereof or comparable terminology are
intended to identify forward-looking statements. These statements
reflect our current views with respect to future events or to
our future activities and involve known and unknown risks,
uncertainties and other factors which may cause our actual
activities, actions or achievements to be materially different from
any future activities, actions or achievements expressed or implied
by the forward-looking statements. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements.
Company Contact:
Derrick C.
Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-cbmg-announces-2020-annual-meeting-of-stockholders-301065079.html
SOURCE Cellular Biomedicine Group